Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder

Completed

• Conditions: Observational; Naturalistic

• Registration Number: NCT00745966
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in Korean Bipolar patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07
• Status Verified: 2008-09
• Primary Completion: 2008-09
• Study First Submitted: 2008-09-02
• Study First Submitted QC: 2008-09-02
• Study First Posted: 2008-09-03
• Last Update Submitted: 2008-10-03
• Last Update Posted: 2008-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent.
• Meet DSM-IV-TR criteria for bipolar disorder (bipolar I disorder, bipolar II disorder) at the time of baseline.

Read More

Exclusion Criteria

• Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history.
• Known intolerance for or lack of response to atypical antipsychotics , as judged by the investigator.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The change from the baseline to week 8 in Short Form of the Quality of Life Enjoyment and satisfaction Questionnaire (Q-LES-Q) score

Secondary Outcome Measures

Name	Time	Method
The change from the baseline to week 8 in CGI-BP and GAF scale score.

Trial Locations

Locations (2)

Research Site; 🇰🇷 Kyunggi-do, Choonchun-si, Korea, Republic of

RFesearch Site; 🇰🇷 Dae-gu, Joong-gu, Korea, Republic of